ATE390135T1 - Verfahren zur verwendung von und zusammensetzungen mit immunomodulatorischen verbindungen zur behandlung und versorgung von myelodysplastischen syndromen - Google Patents

Verfahren zur verwendung von und zusammensetzungen mit immunomodulatorischen verbindungen zur behandlung und versorgung von myelodysplastischen syndromen

Info

Publication number
ATE390135T1
ATE390135T1 AT03726262T AT03726262T ATE390135T1 AT E390135 T1 ATE390135 T1 AT E390135T1 AT 03726262 T AT03726262 T AT 03726262T AT 03726262 T AT03726262 T AT 03726262T AT E390135 T1 ATE390135 T1 AT E390135T1
Authority
AT
Austria
Prior art keywords
care
treatment
compositions containing
methods
myelodysplastic syndrome
Prior art date
Application number
AT03726262T
Other languages
German (de)
English (en)
Inventor
Jerome Zeldis
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32107932&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE390135(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celgene Corp filed Critical Celgene Corp
Application granted granted Critical
Publication of ATE390135T1 publication Critical patent/ATE390135T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AT03726262T 2002-10-15 2003-04-13 Verfahren zur verwendung von und zusammensetzungen mit immunomodulatorischen verbindungen zur behandlung und versorgung von myelodysplastischen syndromen ATE390135T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41846802P 2002-10-15 2002-10-15

Publications (1)

Publication Number Publication Date
ATE390135T1 true ATE390135T1 (de) 2008-04-15

Family

ID=32107932

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03726262T ATE390135T1 (de) 2002-10-15 2003-04-13 Verfahren zur verwendung von und zusammensetzungen mit immunomodulatorischen verbindungen zur behandlung und versorgung von myelodysplastischen syndromen

Country Status (19)

Country Link
US (3) US7189740B2 (OSRAM)
EP (1) EP1487461B1 (OSRAM)
JP (2) JP4481828B2 (OSRAM)
KR (2) KR20070020141A (OSRAM)
CN (2) CN101564390A (OSRAM)
AT (1) ATE390135T1 (OSRAM)
AU (2) AU2003228508B2 (OSRAM)
BR (1) BRPI0315315B1 (OSRAM)
CA (1) CA2477301C (OSRAM)
DE (1) DE60319967T2 (OSRAM)
DK (1) DK1487461T3 (OSRAM)
ES (1) ES2304509T3 (OSRAM)
IL (1) IL168061A (OSRAM)
MX (2) MX358515B (OSRAM)
NZ (2) NZ552052A (OSRAM)
PT (1) PT1487461E (OSRAM)
SI (1) SI1487461T1 (OSRAM)
WO (1) WO2004035064A1 (OSRAM)
ZA (1) ZA200503025B (OSRAM)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU228769B1 (en) * 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
US7629360B2 (en) * 1999-05-07 2009-12-08 Celgene Corporation Methods for the treatment of cachexia and graft v. host disease
US6458810B1 (en) 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
US7812169B2 (en) 2000-11-30 2010-10-12 The Children's Medical Center Corporation Method of synthesis of 4-amino-thalidomide enantiomers
US7091353B2 (en) * 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
US7498171B2 (en) * 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
US7323479B2 (en) * 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
US7393862B2 (en) * 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
US7968569B2 (en) * 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
USRE48890E1 (en) 2002-05-17 2022-01-11 Celgene Corporation Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
ATE466085T1 (de) * 2002-09-09 2010-05-15 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
US7189740B2 (en) * 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US8404716B2 (en) * 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US6943249B2 (en) * 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US6887855B2 (en) 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US7825136B2 (en) * 2003-07-10 2010-11-02 Vertex Pharmaceuticals Incorporated Potentiators of antibacterial activity
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
US20050100529A1 (en) * 2003-11-06 2005-05-12 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
BRPI0417186A (pt) * 2003-12-02 2007-03-06 Celgene Corp método de tratamento de um indivìduo tendo uma hemoglobinopatia ou uma anemia, de modulação da diferenciação de uma célula-tronco ou precursora de cd34+ para uma linhagem de eritróides, e, composição farmacêutica
US20050143344A1 (en) * 2003-12-30 2005-06-30 Zeldis Jerome B. Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
NZ550026A (en) * 2004-03-22 2009-10-30 Celgene Corp Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of skin diseases or disorders
US20050222209A1 (en) * 2004-04-01 2005-10-06 Zeldis Jerome B Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
MXPA06011798A (es) * 2004-04-14 2007-01-16 Celgene Corp Metodos de uso y composiciones que comprenden compuestos inmunomoduladores para el tratamiento y manejo de sindromes mielodisplasticos.
KR20070010184A (ko) * 2004-04-23 2007-01-22 셀진 코포레이션 폐 고혈압증의 치료 및 관리를 위한 면역조절 화합물의사용 방법 및 상기 화합물을 포함하는 조성물
EP1746995A4 (en) * 2004-05-05 2010-03-31 Celgene Corp METHOD OF USE AND COMPOSITIONS COMPRISING IMMUNOMODULATORY COMPOUNDS FOR THE TREATMENT AND MANAGEMENT OF MYELOPROLIFERATIVE DISEASES
KR20070057907A (ko) * 2004-09-03 2007-06-07 셀진 코포레이션 치환된 2-(2,6-디옥소피페리딘-3-일)-1-옥소이소인돌린의제조 방법
CA2588597A1 (en) * 2004-11-23 2006-06-01 Celgene Corporation Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury
DK2380887T3 (da) * 2005-06-30 2013-10-07 Celgene Corp Fremgangsmåder til fremstilling af 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindolin-1,3-dion-forbindelser
US20070066512A1 (en) * 2005-09-12 2007-03-22 Dominique Verhelle Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
KR101434522B1 (ko) 2005-11-09 2014-08-26 오닉스 세라퓨틱스, 인크. 효소 저해를 위한 화합물
CN101374941A (zh) * 2005-12-29 2009-02-25 人类起源公司 采集和保存胎盘干细胞的改良组合物及其使用方法
US20080064876A1 (en) * 2006-05-16 2008-03-13 Muller George W Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
RU2450016C2 (ru) 2006-06-19 2012-05-10 Протеоликс, Инк. Пептидные эпоксикетоны для ингибирования протеасомы
US8877780B2 (en) 2006-08-30 2014-11-04 Celgene Corporation 5-substituted isoindoline compounds
RS52349B (sr) 2006-09-26 2012-12-31 Celgene Corporation 5-supstituisani derivati hinazolinona kao antitumorski agensi
CN101557806A (zh) * 2006-10-19 2009-10-14 细胞基因公司 使用免疫调节化合物治疗和控制螺旋体和其它专性胞内菌疾病的方法和组合物
NZ584425A (en) 2007-09-26 2012-03-30 Celgene Corp 6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same
SI2207791T2 (sl) 2007-10-04 2019-09-30 Onyx Therapeutics, Inc. Kristalinični peptidepoksiketonski proteazni inhibitorji in sinteza aminokislinskih ketoepoksidov
CA2742252A1 (en) * 2007-11-01 2009-05-07 Celgene Corporation Cytidine analogs for treatment of myelodysplastic syndromes
CN101977603A (zh) * 2008-01-29 2011-02-16 细胞基因公司 使用免疫调节化合物来调节cd59水平的方法
US20090298882A1 (en) * 2008-05-13 2009-12-03 Muller George W Thioxoisoindoline compounds and compositions comprising and methods of using the same
EP2695609B1 (en) 2008-05-15 2019-12-11 Celgene Corporation Oral formulations of cytidine analogs and methods of use thereof
EP2796134B1 (en) 2008-10-21 2016-12-07 Onyx Therapeutics, Inc. Combination of the peptide epoxyketone proteasome inhibitor carfilzomib with melphalan for use in the treatment of multiple myeloma
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
NZ592425A (en) 2008-10-29 2013-04-26 Celgene Corp Isoindoline compounds for use in the treatment of cancer
US20120046315A1 (en) * 2008-11-14 2012-02-23 Katrin Rimkus Intermediate and oral administrative formats containing lenalidomide
EP2367553B1 (en) 2008-12-05 2017-05-03 Novo Nordisk A/S Combination therapy to enhance nk cell mediated cytotoxicity
EP2396312A1 (en) 2009-02-11 2011-12-21 Celgene Corporation Isotopologues of lenalidomide
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
EP2391355B1 (en) 2009-05-19 2017-01-18 Celgene Corporation Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
EP2436387B1 (en) 2009-05-25 2018-07-25 Celgene Corporation Pharmaceutical composition comprising crbn for use in treating a disease of the cerebral cortex
CN101696205B (zh) 2009-11-02 2011-10-19 南京卡文迪许生物工程技术有限公司 3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物
EP2498793B1 (en) 2009-11-13 2019-07-10 Onyx Therapeutics, Inc. Oprozomib for use in metastasis suppression
RU2012131164A (ru) 2009-12-22 2014-01-27 Селджин Корпорейшн (метилсульфонил)этил-бензол-изоиндолиновые производные и их терапевтическое применение
LT3202460T (lt) 2010-02-11 2019-10-10 Celgene Corporation Arilmetoksi izoindolino dariniai ir kompozicijos, apimantys ir jų panaudojimo būdus
AU2011223795B2 (en) 2010-03-01 2015-11-05 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
KR20130094185A (ko) 2010-04-07 2013-08-23 오닉스 세라퓨틱스, 인크. 결정성 펩티드 에폭시케톤 면역프로테아좀 저해제
AU2011237747B2 (en) 2010-04-07 2015-07-23 Celularity Inc. Angiogenesis using placental stem cells
US20110301199A1 (en) * 2010-06-07 2011-12-08 Telik, Inc. Compositions and methods for treating myelodysplastic syndrome
US8759303B2 (en) 2010-06-07 2014-06-24 Telik, Inc. Compositions and methods for treating myelodysplastic syndrome
WO2011160042A2 (en) 2010-06-18 2011-12-22 Makoto Life Sciences, Inc. Prpk-tprkb modulators and uses thereof
AR093183A1 (es) 2010-12-31 2015-05-27 Anthrogenesis Corp Aumento de la potencia de celulas madre de placenta usando moleculas de arn moduladoras
ES2673114T3 (es) 2011-01-10 2018-06-19 Celgene Corporation Derivados de fenetilsulfona isoindolina como inhibidores de PDE 4 y/o citoquinas
WO2012106299A1 (en) 2011-01-31 2012-08-09 Celgene Corporation Pharmaceutical compositions of cytidine analogs and methods of use thereof
CA2829570C (en) 2011-03-11 2019-05-07 Celgene Corporation Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
WO2012135299A1 (en) 2011-03-28 2012-10-04 Deuteria Pharmaceuticals Inc 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
CN103619864A (zh) 2011-03-31 2014-03-05 细胞基因国际有限公司 5-氮杂胞苷的合成
CN103688176A (zh) 2011-04-29 2014-03-26 细胞基因公司 利用cereblon作为预报因子治疗癌和炎性疾病的方法
PL2714059T3 (pl) 2011-06-01 2019-04-30 Celularity Inc Leczenie bólu z użyciem komórek macierzystych łożyska
US20140221427A1 (en) 2011-06-22 2014-08-07 Celgene Corporation Isotopologues of pomalidomide
WO2013022872A1 (en) 2011-08-10 2013-02-14 Celgene Corporation Gene methylation biomarkers and methods of use thereof
RU2627471C2 (ru) 2011-09-14 2017-08-08 Селджин Корпорейшн Препараты { 2-[(1s)-1-(3-этокси-4-метоксифенил)-2-метансульфонилэтил]-3-оксо-2,3-дигидро-1h-изоиндол-4-ил} амида циклопропанкарбоновой кислоты
AU2012362562B2 (en) 2011-12-27 2017-11-02 Amgen (Europe) GmbH Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione
EP2817300B1 (en) 2012-02-21 2018-04-25 Celgene Corporation Solid forms of 3-(4-nitro-1-oxoisoindolin-2-yl)piperidine-2,6-dione
CA3136093C (en) 2012-06-29 2025-07-08 Celgene Corporation METHODS FOR DETERMINING THE EFFICACY OF A DRUG USING PROTEINS ASSOCIATED WITH CEREBLON
US20140105921A1 (en) 2012-07-09 2014-04-17 Onyx Therapeutics, Inc. Prodrugs of Peptide Epoxy Ketone Protease Inhibitors
LT2882737T (lt) 2012-08-09 2019-04-25 Celgene Corporation (s)-3-(4-((4-morfolinometil)benzil)oksi)-1-oksoizoindolin-2-il)piperidin-2,6-diono hidrochlorido kieta forma
US9587281B2 (en) 2012-08-14 2017-03-07 Celgene Corporation Cereblon isoforms and their use as biomarkers for therapeutic treatment
CN105102612B (zh) * 2012-12-06 2020-11-17 恩立夫克治疗有限责任公司 治疗性凋亡细胞制剂、其制备方法以及其用途
EP2943201B2 (en) 2013-01-14 2020-07-29 Deuterx, LLC 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
WO2014116573A1 (en) 2013-01-22 2014-07-31 Celgene Corporation Processes for the preparation of isotopologues of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
EP2764866A1 (en) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibitors of nedd8-activating enzyme
WO2014152833A1 (en) 2013-03-14 2014-09-25 Deuterx, Llc 3-(substituted-4-oxo-quinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
CA2907908A1 (en) 2013-04-02 2014-10-09 Celgene Corporation Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers
EA201591931A1 (ru) 2013-04-09 2016-05-31 Ликсте Байотекнолоджи, Инк. Композиции оксабициклогептанов и оксабициклогептенов
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
UA117141C2 (uk) 2013-10-08 2018-06-25 Селджин Корпорейшн Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону
WO2015108889A1 (en) 2014-01-15 2015-07-23 Celgene Corporation Formulations of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione
WO2015116802A1 (en) 2014-01-29 2015-08-06 Otsuka Pharmaceutical Co., Ltd. Device-based risk management of a therapeutic
US10092555B2 (en) 2014-06-27 2018-10-09 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
EP3171870B1 (en) 2014-07-24 2021-10-20 H. Lee Moffitt Cancer Center And Research Institute, Inc. Protein phosphatase 2a inhibitors for treating myelodysplastic syndromes
PT3182996T (pt) 2014-08-22 2023-03-21 Celgene Corp Métodos de tratamento de mieloma múltiplo com compostos imunomoduladores em combinação com anticorpos
US9694084B2 (en) 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2016105518A1 (en) 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
US10488411B2 (en) * 2015-05-01 2019-11-26 H. Lee Moffitt Cancer Center And Research Institute, Inc. Inflammasome activation in myelodysplastic syndromes
WO2017007612A1 (en) 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
HUE049620T2 (hu) 2015-08-17 2020-09-28 Kura Oncology Inc Módszerek rákos páciensek kezelésére farneziltranszferáz inhibitorokkal
US9809603B1 (en) 2015-08-18 2017-11-07 Deuterx, Llc Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
US10830762B2 (en) 2015-12-28 2020-11-10 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
KR20190015300A (ko) * 2016-06-06 2019-02-13 셀진 코포레이션 2-(4-클로로페닐)-n-((2-(2,6-다이옥소피페리딘-3-일)-1-옥소아이소인돌린-5-일)메틸)-2,2-다이플루오로아세트아마이드에 의한 혈액 악성종양의 치료
WO2018013689A1 (en) 2016-07-13 2018-01-18 Celgene Corporation Solid dispersions and solid forms comprising 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione, method of preparation and use thereof
WO2018026894A1 (en) * 2016-08-03 2018-02-08 Celgene Corporation Methods of treatment of myelodysplastic syndrome
IL290857B2 (en) 2016-12-08 2023-03-01 Lixte Biotechnology Inc Oxabicycloheptanes for immune response modulation
WO2018129533A1 (en) 2017-01-09 2018-07-12 Shuttle Pharmaceuticals, Llc Selective histone deacetylase inhibitors for the treatment of human disease
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
US10093647B1 (en) 2017-05-26 2018-10-09 Celgene Corporation Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione dihydrate, compositions and methods of use thereof
US10093648B1 (en) 2017-09-22 2018-10-09 Celgene Corporation Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate, compositions and methods of use thereof
US10093649B1 (en) 2017-09-22 2018-10-09 Celgene Corporation Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate, compositions and methods of use thereof
WO2019113269A1 (en) 2017-12-08 2019-06-13 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
US11407723B2 (en) 2018-01-09 2022-08-09 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
WO2019191112A1 (en) * 2018-03-26 2019-10-03 C4 Therapeutics, Inc. Cereblon binders for the degradation of ikaros
TW202108170A (zh) 2019-03-15 2021-03-01 美商庫拉腫瘤技術股份有限公司 以法呢基轉移酶(farnesyltransferase)抑制劑治療癌症患者之方法
KR20230133317A (ko) * 2021-01-18 2023-09-19 액티브 바이오테크 에이비 골수이형성 증후군의 치료에 이용하기 위한 타스퀴니모드또는 이의 약제학적으로 허용가능한 염

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5288487A (en) 1989-02-28 1994-02-22 Morinaga Milk Industry Co., Ltd. Human monocyte-macrophage-CSF preparations
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
JPH05503302A (ja) 1990-10-12 1993-06-03 アムジエン・インコーポレーテツド 巨核球成熟因子
AU1531492A (en) 1991-02-14 1992-09-15 Rockefeller University, The Method for controlling abnormal concentration tnf alpha in human tissues
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5360352A (en) 1992-12-24 1994-11-01 The Whitaker Corporation Wire retainer for current mode coupler
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6228879B1 (en) 1997-10-16 2001-05-08 The Children's Medical Center Methods and compositions for inhibition of angiogenesis
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US20010056114A1 (en) 2000-11-01 2001-12-27 D'amato Robert Methods for the inhibition of angiogenesis with 3-amino thalidomide
US5698579A (en) 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5643915A (en) 1995-06-06 1997-07-01 Andrulis Pharmaceuticals Corp. Treatment of ischemia/reperfusion injury with thalidomide alone or in combination with other therapies
HU228769B1 (en) 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
ATE530542T1 (de) 1996-07-24 2011-11-15 Celgene Corp Amino substituierte 2-(2,6-dioxopiperidin-3-yl)- phthalimide zur verringerung der tnf-alpha-stufen
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US5798368A (en) 1996-08-22 1998-08-25 Celgene Corporation Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
CA2262906C (en) 1996-08-12 2006-10-31 Celgene Corporation Novel immunotherapeutic agents and their use in the reduction of cytokine levels
DK1920773T3 (da) 1996-11-05 2011-03-28 Childrens Medical Center Thalidomid og dexamethason til behandling af tumorer
US5874448A (en) 1997-11-18 1999-02-23 Celgene Corporation Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels
US5955476A (en) 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
US6096757A (en) * 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
BR9908811A (pt) 1998-03-16 2000-12-05 Celgene Corp Composto, composição farmacêutica e seu uso no tratamento de mamìferos
JPH11286455A (ja) 1998-03-31 1999-10-19 Kanebo Ltd 骨髄異形成症候群治療薬
US6355349B2 (en) * 1998-04-23 2002-03-12 Jeffrey J. Chizmas Reflectively enhanced coated cable
US6673828B1 (en) 1998-05-11 2004-01-06 Children's Medical Center Corporation Analogs of 2-Phthalimidinoglutaric acid
US6020358A (en) 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
ATE306469T1 (de) 1999-03-18 2005-10-15 Celgene Corp Substituierte 1-oxo- und 1,3-dioxoisoindoline und ihre verwendung in pharmazeutischen zusammensetzungen zur senkung des spiegels inflammatorisch wirkender cytokine
US20010021380A1 (en) * 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US7182953B2 (en) 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
AU2001249755A1 (en) 2000-03-31 2001-10-15 Celgene Corporation Inhibition of cyclooxygenase-2 activity
NZ522767A (en) 2000-05-15 2004-07-30 Celgene Corp Thalidomide and a topoisomerase inhibitor for the treatment of cancer
DE60118547T2 (de) 2000-05-15 2007-02-01 Celgene Corp. Pharmazeutische zusammensetzung zur behandlung von kolorektalem krebs welche thalidomid und irinotecan enthält
US6458810B1 (en) 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
US7091353B2 (en) * 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
US20030045552A1 (en) 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
ATE450529T1 (de) 2001-02-27 2009-12-15 Governement Of The United Stat Analoga von thalidomid als angiogeneseinhibitoren
ES2325916T3 (es) 2001-08-06 2009-09-24 The Children's Medical Center Corporation Actividad antiangiogenica de analogos de talidomida sustituidos con nitrogeno.
JP2005533748A (ja) * 2002-03-08 2005-11-10 シグナル ファーマシューティカルズ，インコーポレイテッド 増殖性障害および癌を治療、予防、または管理するための併用療法
US7498171B2 (en) * 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
EP2915533B1 (en) 2002-05-17 2017-09-13 Celgene Corporation Pharmaceutical compositions for treating cancer
US7968569B2 (en) * 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
CN1668296A (zh) 2002-05-17 2005-09-14 细胞基因公司 使用选择性细胞因子抑制性药物用于治疗和控制癌症和其它疾病的方法及组合物
BR0312597A (pt) * 2002-07-11 2005-05-10 Combinatorx Inc Combinações de drogas para o tratamento de neoplasmas
US7189740B2 (en) * 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US20040091455A1 (en) 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
EP1744748A4 (en) 2004-04-14 2009-08-12 Celgene Corp METHOD FOR USE OF SELECTIVE CYTOKINE-INHIBITORY MEDICAMENTS AND COMPOSITIONS CONTAINING THEREOF FOR THE TREATMENT AND SUPPLY OF MYELODYSPLASTIC SYNDROMES
MXPA06011798A (es) 2004-04-14 2007-01-16 Celgene Corp Metodos de uso y composiciones que comprenden compuestos inmunomoduladores para el tratamiento y manejo de sindromes mielodisplasticos.

Also Published As

Publication number Publication date
US20080161360A1 (en) 2008-07-03
NZ539533A (en) 2008-03-28
EP1487461A4 (en) 2005-09-21
BRPI0315315B8 (OSRAM) 2021-05-25
DK1487461T3 (da) 2008-07-21
AU2003228508B2 (en) 2008-10-23
JP2007045839A (ja) 2007-02-22
EP1487461A1 (en) 2004-12-22
US7393863B2 (en) 2008-07-01
US7863297B2 (en) 2011-01-04
JP2006507271A (ja) 2006-03-02
US20070196330A1 (en) 2007-08-23
WO2004035064A1 (en) 2004-04-29
NZ552052A (en) 2008-03-28
MX358515B (es) 2018-08-24
DE60319967D1 (de) 2008-05-08
ES2304509T3 (es) 2008-10-16
CN1713917A (zh) 2005-12-28
ZA200503025B (en) 2006-06-28
BRPI0315315B1 (pt) 2017-09-19
SI1487461T1 (sl) 2008-08-31
KR100711181B1 (ko) 2007-04-24
CN100579527C (zh) 2010-01-13
DE60319967T2 (de) 2009-04-16
CN101564390A (zh) 2009-10-28
US20040220144A1 (en) 2004-11-04
AU2003228508A1 (en) 2004-05-04
US7189740B2 (en) 2007-03-13
CA2477301C (en) 2009-09-01
EP1487461B1 (en) 2008-03-26
JP4481828B2 (ja) 2010-06-16
BR0315315A (pt) 2005-08-16
PT1487461E (pt) 2008-07-04
AU2008202638B2 (en) 2011-12-22
KR20050053769A (ko) 2005-06-08
MXPA05003888A (es) 2005-06-22
AU2008202638A1 (en) 2008-07-03
IL168061A (en) 2010-04-15
KR20070020141A (ko) 2007-02-16
HK1073427A1 (en) 2005-10-07
CA2477301A1 (en) 2004-04-29

Similar Documents

Publication Publication Date Title
ATE390135T1 (de) Verfahren zur verwendung von und zusammensetzungen mit immunomodulatorischen verbindungen zur behandlung und versorgung von myelodysplastischen syndromen
WO2005044178A3 (en) Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
MXPA05004778A (es) Metodos de uso y composiciones que contienen compuestos inmunomoduladores para el tratamiento y manejo de enfermedades mieloproliferativas.
EA200601253A1 (ru) Преимущественно линейная шипучая лекарственная форма фентанила для перорального применения и способы введения
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
DE60328974D1 (de) (+)-2-ä1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethylü-4-acetylaminoisoindolin-1,3-dion zur verwendung in der behandlung von psoriasis durch orale verabreichung
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
DK1654253T3 (da) Substituerede 3-pyrrolidinindolderivater
EA200970595A1 (ru) Производные замещенных индазолов, активные в качестве ингибиторов киназ
EA200601901A1 (ru) Композиции, содержащие иммуномодулирующие соединения для лечения и управления течением миелодиспластических синдромов и способы с их использованием
BR0309345A (pt) Composto ou sais farmaceuticamente aceitáveis do mesmo, composição farmacêutica, uso de um composto, e, métodos de tratamento ou profilaxia de doenças ou condições humanas, de distúrbios psicóticos ou de distúrbios de dano intelectual, e de jetlag, interrupção do hábito de fumar, dependência de nicotina, ânsias, dor e colite ulcerativa
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
CY1113462T1 (el) Μορφη δοσολογιας περιεχουσα παντοπραζολη ως δραστικο συστατικο
BRPI0511224A (pt) método para preparar uma composição contendo antagonistas de opióides, produto contendo antagonistas de opióides, composição contendo antagonistas de opióides, formulação de dosagem injetável, kit, método para prevenir ou tratar um efeito colateral associado com um opióide num paciente, e para tratar ou impedir dor num paciente
BRPI0413438A (pt) derivados de pirimidilpirrol ativos como inibidores de cinase
SE0302573D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
WO2004034962A3 (en) Selective cytokine inhibitory drugs for treating myelodysplastic syndrome
SE0302570D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
WO2004041190A3 (en) Composition for the treatment of macular degenration
TW200503683A (en) Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
SE0302572D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
EA200870223A1 (ru) Производные бензоизоиндола для лечения боли
WO2005039497A3 (en) Methods and compositions comprising thalidomide for treatment of fibromyalgia
BRPI0418743A (pt) métodos de tratamento, prevenção ou controle de uma sìndrome mielodisplásica, de redução ou evitação de um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de uma sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária única, e, kit
DE602004017214D1 (de) Antibakterielle und/oder gegen protozoen wirksame nitroimidazolderivatverbindungen mit ureasehemmender wirkung, verfahren zur herstellung dieser verbindungen und deren verwendung in pharmazeutischen zusammensetzungen und medikamenten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1487461

Country of ref document: EP